ライフサイエンスコーパス: CpG oligonucleotide

1 rder structure and endosomal location of the CpG oligonucleotide.

2 IL-12, and IL-6 was secreted in response to CpG oligonucleotide.

3 gins produced IFN-alpha when stimulated with CpG oligonucleotides.

4 respond to structurally distinct classes of CpG oligonucleotides.

5 he presence of agonistic Abs against CD40 or CpG oligonucleotides.

6 pG motifs abolished the protective effect of CpG oligonucleotides.

7 in response to cytosine-phosphate-guanosine (CpG) oligonucleotides.

8 receptor 9, and we found that the synthetic CpG oligonucleotide 2006 (CpG) reduced the frequency of

9 tes on the cell surface, where it recognizes CpG oligonucleotide 2006.

10 We demonstrate that CpG oligonucleotides activate a TLR9-independent pathway

11 We show that siRNA synthetically linked to a CpG oligonucleotide agonist of toll-like receptor (TLR)9

12 c precursor cells isolated from human blood, CpG oligonucleotides alone were superior to GMCSF in pro

13 g conventional Toll-like receptor 9 ligands (CpG oligonucleotides), although it could be demonstrated

14 lls enhances cell proliferation triggered by CpG oligonucleotides and decreases sensitivity to dexame

15 CpG oligonucleotides and imiquimod, prototypic drugs in

16 In addition, preclinical data on CpG oligonucleotides appear to be encouraging, particula

17 The effects of both anti-CD40 and CpG oligonucleotides are dependent upon induction of IL-

18 MNs coated with Ova as a model allergen and CpG oligonucleotide as an adjuvant (MNs-CIT) into the sk

19 intracerebral deposition of TLR9-activating CpG oligonucleotides, but not following non-CpG oligonuc

20 h peptide and cytosine-guanine dinucleotide (CpG) oligonucleotide, but not control oligonucleotide, s

21 e have recently shown that the TLR9 agonists CpG oligonucleotides can be used for targeted siRNA deli

22 could also produce IFN-alpha in response to CpG oligonucleotides, consistent with the observations o

23 Engaging TLR9 with CpG oligonucleotide contributes to the development of IL

24 zation and by adjuvants such as unmethylated CpG oligonucleotide (CpG) and LPS that induce T helper t

25 muramyl dipeptide (MDP), LPS, and a B-class CpG oligonucleotide (CpG-B), can substitute for gut flor

26 Synthetic CpG oligonucleotides (CpG DNA) are a relatively new clas

27 Hypomethylated CpG oligonucleotides (CpG) are not only potent adjuvants

28 d stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastas

29 es adjuvanted by a robust formulation of the CpG oligonucleotide delivered in emulsion were superior

30 coproteins adjuvanted with MF59 containing a CpG oligonucleotide elicited strong CD4(+) T helper resp

31 ted that oropharyngeal delivery of synthetic CpG-oligonucleotides elicited minimal lung inflammation

32 e contention that repeated administration of CpG-oligonucleotides enhances the effect of peptide and

33 These findings suggest that a CpG oligonucleotide given intratumorally may increase th

34 Compared with non-CpG oligonucleotides, i.v. treatment with CpG oligonucle

35 pairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemother

36 s a role for liver NK1.1(+) cells, IL-22 and CpG oligonucleotides in the induction of tolerance to is

37 CpG oligonucleotides, but not following non-CpG oligonucleotide injection or after aseptic cryoinjur

38 Three classes of CpG oligonucleotide ligands for Toll-like receptor (TLR)

39 pathway were functional, since class B and C CpG oligonucleotide ligands stimulated production of RAN

40 Remarkably, adjuvantation with CpG oligonucleotides markedly increased GC T(FH) and GC

41 Immunostimulatory CpG oligonucleotides (ODN) activate cells that express T

42 Synthetic CpG oligonucleotides (ODN) have potent immunostimulatory

43 Immunostimulatory CpG oligonucleotides (ODN) show promise as immune adjuva

44 se surface expression of CD80 in response to CpG oligonucleotides (ODN).

45 of functional nanodiamonds (fNDs) to deliver CpG oligonucleotides (ODNs) for sustained immunostimulat

46 Administration of CpG oligonucleotide or cationic lipid 3beta-[N-(N',N'-di

47 st, poly I:C, but not by other TLR agonists, CpG oligonucleotide or Toxoplasma gondii antigen.

48 activated by exposure to LPS, nonmethylated CpG oligonucleotides, or CD40L.

49 on-CpG oligonucleotides, i.v. treatment with CpG oligonucleotides resulted in higher systemic concent

50 ced IL-10-secreting Treg with TLR9 agonists, CpG oligonucleotides, resulted in decreased IL-10 and IF

51 he efficiency of EBV B-CLL transformation of CpG oligonucleotide-stimulated cells by incubating patie

52 Vaccination of T1D mice with a CpG oligonucleotide TLR9 agonist (ODN 1585) enhances exp

53 polysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-depen

54 lpha secretion from pDCs and that inhibitory CpG oligonucleotide treatment diminished HSV-induced IFN

55 cytokine production and tumor necrosis after CpG-oligonucleotide treatment and deficient production o

56 blockade of the inhibitory receptor CD96 or CpG-oligonucleotide treatment.

57 d uninfected individuals to the TLR9 agonist CpG oligonucleotide type B (CpG-B) in the presence and a

58 The protective effect of CpG oligonucleotides was observed in mice with either a